Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from TruScreen Group Ltd. ( (AU:TRU) ) is now available.
TruScreen Group Limited has signed an agreement with Hangzhou Dalton Bioscience Limited to distribute DaltonBio’s HPV-related In Vitro Diagnostics products in India. This collaboration aims to improve cervical cancer screening in India, where the disease is a significant public health concern. The agreement is expected to enhance TruScreen’s market presence in India and potentially lead to similar agreements in other countries, contributing to the company’s strategic growth and offering a comprehensive solution for cervical cancer detection.
More about TruScreen Group Ltd.
TruScreen Group Limited is a global leader in AI-enabled cervical cancer screening. The company focuses on providing innovative solutions for cervical cancer detection and has recently expanded its operations in India by partnering with local distributors to enhance access to its technology.
Average Trading Volume: 154,474
Technical Sentiment Signal: Buy
Current Market Cap: A$15.39M
Learn more about TRU stock on TipRanks’ Stock Analysis page.